Eli Lilly vs Pfizer: a complete comparison of OVR ratings, fundamentals, volatility, and characteristics.
LLY is rated 91 OVR (S-Tier (Elite)) — Eli Lilly's Mounjaro and Zepbound obesity drugs represent a generational product cycle. Demand subst
PFE is rated 64 OVR (C-Tier (Speculative)) — Pfizer's post-COVID revenue collapse removed billions from annual revenue. The pipeline must replace
| METRIC | LLY (Eli Lilly) | PFE (Pfizer) |
|---|---|---|
| OVR Rating | 91 | 64 |
| Tier | S-Tier (Elite) | C-Tier (Speculative) |
| Momentum | 80/100 | 28/100 |
| Stability | 85/100 | 70/100 |
| Value Score | 50/100 | 78/100 |
| Revenue Growth | +36% | -41% |
| P/E Ratio | 48x | 14x |
| Beta (Volatility) | 0.65 | 0.55 |
| Market Cap | $740B | $150B |
| Dividend Yield | 0.6% | 6.1% |
| S&P 500 | Yes | Yes |
| NFL Comparison | Patrick Mahomes | Cam Newton |
| Sector | Healthcare | Healthcare |
Eli Lilly's Mounjaro and Zepbound obesity drugs represent a generational product cycle. Demand substantially exceeds supply. The obesity drug market is projected to be over $100 billion annually by 2030.
Pfizer's post-COVID revenue collapse removed billions from annual revenue. The pipeline must replace this shortfall. Trading at 14x P/E — cheap only if the pipeline delivers.
Explore both on MarketMVP
Free platform · Sports-style player ratings for every stock
OPEN MARKETMVP FREE →Educational purposes only. MarketMVP OVR scores, tiers, and athlete comparisons are proprietary educational tools — not financial advice, investment ratings, or recommendations to buy or sell any security. Always conduct your own research. Full disclaimer